# Cilostazol Following Peripheral Endovascular Procedures

Study · id `cardio:ct-nct02770274` · Cardiovascular Atlas · release `a25293eeae6350fb` (public)

> General information from published sources, not medical advice, and not reviewed by clinicians. Check the cited source before relying on anything here. Sponsors do not influence what this atlas says.

The atlas's own text and curation may be reused under Creative Commons Attribution-NonCommercial 4.0 International (CC BY-NC 4.0, https://creativecommons.org/licenses/by-nc/4.0/): credit the atlas, and do not use it commercially without a licence from the owner. See the atlas About page. Text quoted from a source stays under that source's own terms, given as the source's reuse\_basis. The atlas's reuse terms do not cover it. The downloads list each quotation with its source in third\_party\_quotations.

**Registry record.** Assembled by a program from [ClinicalTrials.gov record NCT02770274](<https://clinicaltrials.gov/study/NCT02770274>), retrieved 31 October 2026. No person wrote or checked this page.

Also called: NCT02770274

Browse, organ or system: Blood vessels  
Browse, condition area: Coronary and vascular disease  

## In plain language

A phase 3 trial registered on ClinicalTrials.gov. The registry status is unknown. It plans to enroll 200 participants.

## Technical summary

Registry record NCT02770274. Randomized; single masking; primary purpose prevention. Start 2016-12 (actual); primary completion 2021-12 (anticipated). Results not posted.

## Key facts

- Design: Interventional study; randomized; single masking; primary purpose prevention
- Phase: Phase 3
- Enrolled: 200 participants (planned count; ClinicalTrials.gov record NCT02770274, source copy `cardio:ctgov-nct02770274-2021-01-12`, retrieved 2026-10-31)
- Started: 2016-12 (actual) (ClinicalTrials.gov record NCT02770274, source copy `cardio:ctgov-nct02770274-2021-01-12`, retrieved 2026-10-31)
- Primary completion: 2021-12 (anticipated) (ClinicalTrials.gov record NCT02770274, source copy `cardio:ctgov-nct02770274-2021-01-12`, retrieved 2026-10-31)
- Completion: 2021-12 (anticipated) (ClinicalTrials.gov record NCT02770274, source copy `cardio:ctgov-nct02770274-2021-01-12`, retrieved 2026-10-31)
- Countries: Greece (ClinicalTrials.gov record NCT02770274, source copy `cardio:ctgov-nct02770274-2021-01-12`, retrieved 2026-10-31)
- Care setting: Not reported
- Registry status: "UNKNOWN" (U.S. National Library of Medicine (ClinicalTrials.gov), source copy `cardio:ctgov-nct02770274-2021-01-12`, retrieved 2026-10-31)

## The registry's words

- Brief title: Cilostazol Following Peripheral Endovascular Procedures
- Acronym: CILO-PER
- Condition: Peripheral Arterial Disease
- Intervention (Drug): Cilostazol
- Intervention (Drug): Aspirin
- Lead sponsor: Attikon Hospital
- Lead sponsor class: OTHER
- Collaborator: University Hospital of Patras
- Collaborator class: OTHER

## Connected pages

- Registry condition terms include this condition: Peripheral artery disease (`cardio:peripheral-artery-disease`)
- Registry intervention name matches this record: Aspirin (`core:aspirin`)
- Registry lists this organization as a collaborator: University Hospital of Patras (`cardio:org-university-hospital-of-patras`)

## Provenance

Content hash: ec1eb5496dbda4ceafab153470090c2690e2c23563fcbf35ca32c95f7eef9899
Last substantive edit: 2026-11-08
Evidence last checked: Not recorded
